Short answer
Edwards Lifesciences (EW) filed an 8-K current report with the SEC on November 19, 2026 reporting Item 1.01 (Entry into a Material Definitive Agreement), Item 2.03 (Creation of a Direct Financial Obligation). Edwards entered an amended and restated five-year credit agreement on November 19, 2026.
Edwards Lifesciences 8-K event analysis
AI summary of each reported item and its exhibits
Item 1.01 · Entry into a Material Definitive Agreement
- Edwards entered an amended and restated five-year credit agreement on November 19, 2026
- Facility refresh replaces the July 15, 2022 credit agreement
- Improved terms and extended maturity strengthen liquidity flexibility and refinancing runway
- Borrowers include Edwards and certain subsidiaries, with Bank of America as administrative agent
Item 2.03 · Creation of a Direct Financial Obligation
- New five-year $750 million multi-currency unsecured revolving facility replaces 2022 credit agreement
- Maturity extended to November 19, 2031, supporting liquidity and general corporate purposes
- Borrowing costs tied to SOFR or base rate plus leverage-based or debt-rating margin
- Capacity expandable by up to $375 million, subject to lender approval and conditions
- No borrowings outstanding at filing date, limiting immediate balance-sheet impact
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Edwards Lifesciences 8-K filings
Get the next EW 8-K as it lands
Follow EW for push alerts, or ask the research agent what this filing means.